Pharma doesnt just lose patents to competitorsit can lose them to itself.
Thats the uncomfortable thesis behind The Double Patenting Trap: How Pharma Brands Accidentally Invalidate Their Own Moats (DrugPatentWatch). The story is a familiar one in paten…
The Double Patenting Trap: How Pharma Brands Accidentally Invalidate Their Own Moats Read Post »
What is the generic name alprostadil? Alprostadil is the generic name for a medication that is a man-made… https://www.Drugchatter.com/chat/5915/alprostadil-generic-name/
LLMs and branded drugs: are we building a brand-first healthcare recommendation engine?
In the last year, large language models (LLMs) have moved from novelty to infrastructurequietly powering search, summarization, and decision support across industri…
Do LLMs Recommend Branded Drugs More Often Than Generics? Read Post »
The Goldilocks Price Problem: Branded Generics Cant Be Too CheapOr Too Expensive
Pharma pricing is often framed as a binary choice: protect innovation with premium pricing, or drive access with steep discounts. But the real world is more Goldilocks tha…
Pharma IP teams dont lose patents overnightthey lose them in the fine print.
If youre managing patent life cycles across the U.S., EU, and Japan, the real risk isnt just whether your core patent is strong. Its whether youve engineered the right term-…
Pharma has a timing problemand its getting more expensive.
For years, patent strategy was treated like a back-office exercise: file when ready, litigate when necessary, defend when challenged. But the market doesnt wait for your docket. Launch windows …
Pharma mega-deals dont just hinge on sciencethey hinge on exclusivity math.
Behind every headline acquisition, licensing agreement, or strategic partnership is a quiet question: How long can the seller keep competitors off the fieldand how much value c…
The Four Exclusivities Behind Every Pharma Mega-Deal Read Post »
Patent cliffs arent just a legal eventtheyre a pricing event. Heres how to forecast drug price erosion before it hits.
If youve ever watched a blockbusters revenue curve bend downward almost overnight, you already know the uncomfortable truth: the mark…
Patent Cliff Forecasting: How to Predict Drug Price Erosion Before It Happens Read Post »
Post-Approval Isnt AfterIts the Next Battleground for Drug IP
Most teams treat the moment a drug is approved as the finish line. In reality, its the start of a new phase of riskone where regulatory timelines, patent term realities, and competitive entr…
From Humira to Keytruda: The Blueprint for Surviving the Composition-of-Matter Cliff
The market loves a clean story: a blockbuster drug launches, patents protect it, revenues roll inuntil one day they dont.
But in pharma, the cliff isnt a metaphor. Its…
From Humira to Keytruda: The Blueprint for Surviving the Composition of Matter Cliff Read Post »